Brain MRI atrophy quantification in MS: From methods to clinical application.

ABSTRACT: Patients with the main clinical phenotypes of multiple sclerosis (MS) manifest varying degrees of brain atrophy beyond that of normal aging. Assessment of atrophy helps to distinguish clinically and cognitively deteriorating patients and predicts those who will have a less-favorable clinical outcome over the long term. Atrophy can be measured from brain MRI scans, and many technological improvements have been made over the last few years. Several software tools, with differing requirements on technical ability and levels of operator intervention, are currently available and have already been applied in research or clinical trial settings. Despite this, the measurement of atrophy in routine clinical practice remains an unmet need. After a short summary of the pathologic substrates of brain

SUBMITTER: Rocca MA 

PROVIDER: S-EPMC5272969 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature